SEARCH · PubMed Health

Results for “Trimipramine”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

PubMed1979

Serum concentration of trimipramine (Surmontil) and gastric secretion of acid and pepsin following peroral administration of the drug in healthy humans.

Previous blind studies have shown an increased rate of healing of both duodenal and gastric ulcers following 4 weeks peroral administration of 50 mg trimipramine. The present study shows the effect of 50 mg trimipramine perorally on gastric secretion in relation to that of 25 mg of the drug and placebo. At regular intervals blood specimens were obtained for determination of the serum concentration of trimipramine. In 9 healthy young students it was found that the estimated stabilized values of volume and acid output following 50 mg trimipramine, 33 ml and 3.9 mmol/15 min, respectively, were significantly lower than those following the smallest dose, 37 ml and 4.6 mmol/15 min, respectively. On the other hand, no significant changes of gastric secretion were observed following the peroral administration of 25 mg trimipramine when compared to placebo. Following 50 mg trimipramine the output of pepsin was reduced by about 25%. The values of serum concentration of trimipramine were about 200 nmol/1 at 100 min after administration of 50 mg trimipramine and decreased gradually, whereas the values following the smaller dose were about half of those after the larger one. The results indicate that about 50 mg trimipramine is needed for obtaining a reduction of gastric secretions. Future studies may show whether 25 mg trimipramine, which does not suppress acid secretion when given perorally, is able to promote peptic ulcer healing.

Administration, Oral↗

PubMed1978

Trimipramine in the treatment of gastric ulcer.

Forty patients with endoscopically confirmed gastric ulcers, completed a double-blind study comparing trimipramine with placebo during 4 weeks' treatment. The daily dose of trimipramine was 50 mg given before bedtime. No serious side-effects occurred. After four weeks' treatment 12 of the 20 patients receiving trimipramine had endoscopically completely healed ulcers, while in the placebo group only 4 of the 20 ulcers were healed (P = 0.025). With regard to the patients' complaints, a distinct and statistically significant improvement was also observed in the patients receiving trimipramine (P = 0.025). It is assumed that the previously shown antisecretory effect of the drug, together with the sedative and anti-depressive effect, make trimipramine a valuable drug in the treatment of peptic ulcer disease.

Adult↗

PubMed1979

Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients.

A study was carried out in which 135 mildly or moderately depressed outpatients were randomly allocated to one of five groups receiving six weeks' treatment weith antidepressant drugs. The groups received a tricyclic antidepressant (trimipramine; mean dose 106 mg at night) or a monoamine oxidase inhibitor (MAOI) (phenelzine or isocarboxazid; mean doses 45 and 32 mg/day respectively), or a combination of the two (phenelzine plus trimipramine or isocarboxazid plus trimipramine). Various scales were used to measure depression before and at one, three, and six weeks of treatment, and results were assessed blindly. The tricyclic antidepressant was found to be consistently superior to the MAOIs and the combined treatments. Some differential indicators of response to the various antidepressants were found--for example, patients with initial complaints of dizziness, suicidal ideas, irritability, and insomnia and a longer duration of illness were more likely to respond to trimipramine--but these were of only modest significance. Side effects were not troublesome in any group. It is concluded that neither MAOIs nor MAOIs combined with tricyclic antidepressants are the treatment of first choice in unselected outpatients with mild or moderate depression.

Adult↗

PubMed1979

Protection by trimipramine against gastric mucosal barrier dysfunction induced by ethanol + HC1 in rats.

The effects of trimipramine (5 mg . kg-1 . h-1 intravenously) on the changes in gastric mucosal function evoked by 20% ethanol + HCl has been stuided in rats. The magnitude of the changes in potential difference, ionic fluxes (H+, Na+, and K+), and mucosal lesion score induced by ethanol + HCl were significantly less in animals treated with trimipramine than in control animals. It is concluded that trimipramine decreases the gastric mucosal damage produced the ethanol + HCl in rats. This activity may be responsible, at least in part, for the beneficial effect of trimipramine treatment in peptic ulcer disease.

Animals↗

PubMed1979

A double-blind controlled trial of amineptine versus trimipramine in depression.

A double-blind controlled trial was carried out in 50 depressed out-patients to compare the effectiveness and tolerability of amineptine (200 mg per day) with that of trimipramine (75 mg per day). Patients were allocated at random to receive one or other of the trial drugs over a period of 45 days. Assessments were made before, during and after treatment of a number of target symptom clusters. Whilst overall response to treatment was the same with both drugs, trimipramine was superior in those patients presenting with anxiety and insomnia. Amineptine, however, was more effective not only against depressive mood and psychomotor retardation, but also against loss of libido, hypochondriacal features and social withdrawal. Both drugs were relatively well tolerated, but trimipramine had a sedative effect which proved troublesome in some patients.

Adult↗

PubMed1979

[Differential indication of trimipramine - results of a controlled multiclinical study].

The antidepressants trimipramine and imipramine were compared within the framework of a multiclinical study performed under the conditions of a controlled clinical experiment. There has been found a time-different remission of affective und psychomotoric symptoms. The panthymoleptic action of trimipramine and other antidepressants is discussed with reference to these results. Trimipramine influences psychotic states, especially if in depression anxiety is combined with agitation, also in hypochondriac forms of depression.

Clinical Trials as Topic↗

PubMed1979

Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema.

Twelve men with severe and long-standing atopic eczema were admitted to a double-blind trial to establish the effects of trimeprazine tartrate, trimipramine maleate, and placebo on nocturnal scratching. Neither of the drugs altered the likelihood of a scratching bout beginning in wakefulness or in any stage of sleep. However, both drugs, especially trimipramine, made sleep less broken, and the reduced time spent in stage 1 of sleep accounted for a modest reduction in the overall amount of scratching during the night.

Adult↗

PubMed1979